Dimensional Fund Advisors LP cut its holdings in bluebird bio Inc (NASDAQ:BLUE) by 9.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,520 shares of the biotechnology company’s stock after selling 13,406 shares during the period. Dimensional Fund Advisors LP owned 0.24% of bluebird bio worth $20,640,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in BLUE. Los Angeles Capital Management & Equity Research Inc. raised its position in bluebird bio by 662.5% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 135,086 shares of the biotechnology company’s stock worth $21,202,000 after acquiring an additional 117,370 shares during the period. First Trust Advisors LP raised its position in bluebird bio by 22.7% in the second quarter. First Trust Advisors LP now owns 368,708 shares of the biotechnology company’s stock worth $57,869,000 after acquiring an additional 68,258 shares during the period. ARK Investment Management LLC raised its position in bluebird bio by 33.4% in the second quarter. ARK Investment Management LLC now owns 263,321 shares of the biotechnology company’s stock worth $41,328,000 after acquiring an additional 65,922 shares during the period. LMR Partners LLP bought a new position in bluebird bio in the second quarter worth approximately $9,934,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of bluebird bio in the second quarter worth $9,070,000. Institutional investors and hedge funds own 98.45% of the company’s stock.
In related news, Director James Mandell sold 1,000 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $150.77, for a total transaction of $150,770.00. Following the completion of the transaction, the director now directly owns 1,568 shares of the company’s stock, valued at $236,407.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jeffrey T. Walsh sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $175.40, for a total transaction of $3,508,000.00. Following the transaction, the insider now directly owns 44,238 shares of the company’s stock, valued at $7,759,345.20. The disclosure for this sale can be found here. Insiders have sold 62,859 shares of company stock valued at $10,029,606 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.
A number of analysts have recently issued reports on BLUE shares. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research note on Friday, June 15th. Evercore ISI raised shares of bluebird bio from an “in-line” rating to an “outperform” rating and increased their price objective for the stock from $175.00 to $230.00 in a research note on Tuesday, June 19th. Gabelli started coverage on shares of bluebird bio in a research note on Thursday, July 12th. They issued a “buy” rating and a $239.00 price objective for the company. Cantor Fitzgerald set a $122.00 price objective on shares of bluebird bio and gave the stock a “sell” rating in a research note on Friday, July 13th. Finally, Maxim Group reduced their price objective on shares of bluebird bio to $163.00 and set a “hold” rating for the company in a research note on Monday, July 30th. Three analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $213.42.
BLUE opened at $126.09 on Friday. The firm has a market cap of $7.91 billion, a P/E ratio of -16.35 and a beta of 1.89. bluebird bio Inc has a fifty-two week low of $123.34 and a fifty-two week high of $236.17.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, August 2nd. The biotechnology company reported ($2.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.30) by ($0.61). The company had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $10.68 million. bluebird bio had a negative net margin of 1,281.01% and a negative return on equity of 31.57%. The business’s revenue was down 53.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.73) earnings per share. As a group, equities analysts predict that bluebird bio Inc will post -10.8 EPS for the current fiscal year.
bluebird bio Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Article: Calculate Your Return on Investment (ROI)
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.